Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Fluorouracil × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 402 Rectal Neoplasms 231 Colonic Neoplasms 188 Stomach Neoplasms 161 Pancreatic Neoplasms 157 Esophageal Neoplasms 117 Breast Neoplasms 100 Neoplasm Metastasis 99 Head and Neck Neoplasms 78 Neoplasms 73 Squamous Cell Carcinoma of Head and Neck 72 Adenocarcinoma Of Esophagus 58 Esophageal Squamous Cell Carcinoma 47 Carcinoma, Hepatocellular 45 Adenocarcinoma 36 Nasopharyngeal Carcinoma 29 Cholangiocarcinoma 28 Gastrointestinal Neoplasms 22 Anus Neoplasms 22 Keratosis, Actinic 21 Carcinoma, Non-Small-Cell Lung 21 Biliary Tract Neoplasms 21 Gallbladder Neoplasms 19 Carcinoma, Squamous Cell 19 Urinary Bladder Neoplasms 18 Bile Duct Neoplasms 18 Liver Neoplasms 17 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Nasopharyngeal Neoplasms 14 Unspecified Adult Solid Tumor, Protocol Specific 12

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡